User:Mr. Ibrahem/Peramivir

Peramivir, sold under the brand name Rapivab, is an antiviral used to treat influenza. It should be given within two days of the start of symptoms. Evidence does not support its use for prevention. It is given by gradual injection in to a vein.

Common side effects include low neutrophils, trouble sleeping, and nausea. Other side effects may include abnormal behavior. Serious side effects may include anaphylaxis and Stevens-Johnson syndrome. It does not appear to be harmful in pregnancy, but such use has not been well studied. It is a neuraminidase inhibitor that is active against both influenza A and B viruses.

Peramivir was approved for medical use in the United States in 2014. While it was approved in Europe in 2018, this approval was subsequently withdrawn. In the United States it costs about 1,000 USD per dose as of 2021.